keyword
MENU ▼
Read by QxMD icon Read
search

Hypercholesterolaemia

keyword
https://www.readbyqxmd.com/read/28811385/circulating-mir-200c-is-up-regulated-in-paediatric-patients-with-familial-hypercholesterolaemia-and-correlates-with-mir-33a-b-levels-implication-of-a-zeb1-dependent-mechanism
#1
Marco D'Agostino, Francesco Martino, Sara Sileno, Francesco Barilla, Sara Beji, Lorenza Marchetti, Fabio Maria Gangi, Luca Persico, Mario Picozza, Anna Montali, Eliana Martino, Cristina Zanoni, Daniele Avitabile, Sandro Parrotto, Maurizio C Capogrossi, Alessandra Magenta
Hypercholesterolaemia provokes reactive oxygen species (ROS) increase and is a major risk factor for cardiovascular diseases (CVD) development. We previously showed that circulating microRNA(miR)-33a/b expression levels were up-regulated in children with familial hypercholesterolaemia (FH). miR-33a/b control cholesterol homoeostasis and recently miR-33b has been demonstrated to directly target the transcription factor ZEB1. The latter acts in a negative feedback-loop with miR-200 family. Our previous studies showed that the ROS-dependent miR-200c up-regulation induces endothelial dysfunction and provokes a ZEB1-dependent apoptosis and senescence...
August 15, 2017: Clinical Science (1979-)
https://www.readbyqxmd.com/read/28809621/cardiovascular-risk-factors-and-mortality-in-children-with-chronic-kidney-disease
#2
Abdullahi Mudi, Caroline Dickens, Cecil Levy, Daynia Ballot
BACKGROUND: Cardiovascular disease (CVD) begins early in children with chronic kidney disease (CKD), and its progression is determined by the presence of single or multiple cardiovascular risk factors (CVRFs). OBJECTIVE: To determine the prevalence of CVRFs in children with CKD and their association with mortality in children on chronic dialysis. METHODS: This comparative cross-sectional study recruited children aged 5 - 18 years with all stages of CKD...
July 28, 2017: South African Medical Journal, Suid-Afrikaanse Tydskrif Vir Geneeskunde
https://www.readbyqxmd.com/read/28799203/efficacy-and-safety-of-alirocumab-in-people-with-prediabetes-vs-those-with-normoglycaemia-at-baseline-a-pooled-analysis-of-10-phase-iii-odyssey-clinical-trials
#3
L A Leiter, D Müller-Wieland, M T Baccara-Dinet, A Letierce, R Samuel, B Cariou
AIM: To assess the lipid-lowering efficacy and safety of alirocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in people with hypercholesterolaemia and prediabetes at baseline vs people with normoglycaemia at baseline in a pooled analysis of 10 ODYSSEY phase III trials. METHODS: People classified as having prediabetes had baseline HbA1c ≥39 mmol/mol (5.7%) and <48 mmol/mol (6.5%), or two baseline fasting plasma glucose values ≥5.6 mmol/l (100 mg/dl) but no more than one fasting plasma glucose value ≥7...
August 11, 2017: Diabetic Medicine: a Journal of the British Diabetic Association
https://www.readbyqxmd.com/read/28791591/age-related-differences-in-non-persistence-with-statin-treatment-in-patients-after-a-transient-ischaemic-attack
#4
Martin Wawruch, Dusan Zatko, Gejza Wimmer, Jan Luha, Sona Wimmerova, Petra Matalova, Peter Kukumberg, Jan Murin, Tomas Tesar, Beata Havelkova, Rashmi Shah
BACKGROUND AND OBJECTIVE: Non-persistence with secondary preventive measures, including medications such as statins, adversely affects the prospects of successful outcomes. This study was aimed at evaluating non-persistence with statin therapy in cohorts of young and elderly patients after a transient ischaemic attack (TIA) and identifying patient-associated characteristics that influence the risk for non-persistence. METHODS: The study cohorts included 797 adult patients who were initiated on statin therapy following a TIA diagnosis between 1 January 2010 and 31 December 2010...
August 8, 2017: Clinical Drug Investigation
https://www.readbyqxmd.com/read/28762762/gdf-15-and-trail-r2-are-powerful-predictors-of-long-term-mortality-in-patients-with-acute-myocardial-infarction
#5
Emma Skau, Egil Henriksen, Philippe Wagner, Pär Hedberg, Agneta Siegbahn, Jerzy Leppert
Background The Proximity Extension Assay proteomics chip provides a large-scale analysis of 92 biomarkers linked to cardiovascular disease or inflammation. We aimed to identify the biomarkers that best predicted long-term all-cause mortality in patients with acute myocardial infarction. Methods In this prospective cohort study, 92 biomarkers were analysed in 847 consecutive patients from the Västmanland Myocardial Infarction Study with a median follow-up of 6.9 years. Results The mean (± standard deviation) age of the patients was 70 (11...
January 1, 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28761685/two-year-clinical-outcomes-of-patients-treated-with-the-dual-therapy-stent-in-a-1000-patient-all-comers-registry
#6
Deborah N Kalkman, Pier Woudstra, Ian B A Menown, Peter den Heijer, Arnoud Wj Van't Hof, Andrejs Erglis, Harry Suryapranata, Karin E Arkenbout, Andrés Iñiguez, Philippe Muller, Jan G Tijssen, Marcel A M Beijk, Robbert J de Winter
OBJECTIVE: The dual-therapy stent combines an abluminal biodegradable drug-eluting coating, with a 'pro-healing' luminal layer. This bioengineered layer attracts circulating endothelial progenitor cells that can differentiate into normal endothelium. Rapid endothelialisation of the stent might allow safe short dual antiplatelet therapy. We aim to assess clinical outcomes in patients treated with this novel device at 2-year follow-up. METHODS: A total of 1000 patients were included in the REMEDEE Registry to evaluate clinical outcomes after treatment with the dual-therapy stent...
2017: Open Heart
https://www.readbyqxmd.com/read/28758710/multimodality-assessment-of-left-ventricular-dysfunction-in-takayasu-arteritis-and-familial-hypercholesterolaemia
#7
Atsushi Okada, Hiroyuki Takahama, Masatsune Ogura, Yoshiaki Morita, Junichi Konma, Shuzo Yoshida, Shigeki Makino, Seiji Takashio, Makoto Amaki, Takahiro Ohara, Takuya Hasegawa, Yasuo Sugano, Hideaki Kanzaki, Mariko Harada-Shiba, Hatsue Ishibashi-Ueda, Satoshi Yasuda, Toshiaki Hanafusa, Toshihisa Anzai
Although left ventricular (LV) systolic dysfunction in patients suffering from Takayasu arteritis (TA) has been reported, little is known regarding the development of heart failure in these patients. We report a novel finding of active TA and familial hypercholesterolaemia presenting with severe LV dysfunction through multimodality assessments of LV systolic dysfunction.
July 31, 2017: ESC Heart Failure
https://www.readbyqxmd.com/read/28758024/serum-lipid-and-glucose-profiles-in-hiv-positive-nigerian-children
#8
EDITORIAL
Olukemi O Ige, Christopher S Yilgwan, Augustine O Ebonyi, Ruth Adah, Idris Adedeji, Esther S Yiltok, Stephen Oguche, Fidelia Bode-Thomas
OBJECTIVES: To describe the fasting serum lipid and glucose profiles of HIV-positive Nigerian children and determine the prevalence and risk factors for dyslipidaemia and hyperglycaemia, which are risk factors for cardiovascular diseases. METHODS: This was a comparative cross-sectional study carried out at the Paediatric Infectious Disease Clinic (PIDC) of the Jos University Teaching Hospital (JUTH) for HIV-positive children and at two primary schools in Jos for HIV-negative children as controls...
July 1, 2017: Journal of Virus Eradication
https://www.readbyqxmd.com/read/28751835/anmco-scientific-statement-clinical-management-of-hypercholesterolaemia-in-patients-with-acute-coronary-syndromes
#9
Furio Colivicchi, Michele Massimo Gulizia, Marcello Arca, Maurizio Giuseppe Abrignani, Gian Piero Perna, Gian Francesco Mureddu, Federico Nardi, Carmine Riccio
LDL cholesterol (LDL-C) reduction after Acute Coronary Syndromes (ACS) is associated with a significant decrease in subsequent atherosclerotic cardiovascular events. Accordingly, international guidelines recommend a reduction of LDL-C below 70 mg/dL in ACS patients. Such a result can be effectively accomplished in most cases by using high intensity statins. In selected cases, the association with ezetimibe may be necessary in order to achieve recommended LDL-C targets. This document outlines management strategies that can be consistently implemented in clinical practice in order to achieve and maintain guidelines recommended therapeutic goals...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28751834/anmco-position-paper-diagnostic-therapeutic-pathway-in-patients-with-hypercholesterolaemia-and-statin-intolerance
#10
Michele Massimo Gulizia, Furio Colivicchi, Marcello Arca, Maurizio Giuseppe Abrignani, Gian Piero Perna, Gian Francesco Mureddu, Federico Nardi, Carmine Riccio
Statins are a class of drugs used to lower total and low-density lipoprotein (LDL)-cholesterol. Clinical trials performed over the last 25 years have shown that these agents are effective in improving cardiovascular outcomes in several different clinical settings. However, in some cases statin treatment may be associated with significant side effects and adverse reactions. The occurrence of these adverse events during statin therapy may cause discontinuation of treatment, and hence the impossibility of achieving recommended lipid goals...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28751833/anmco-iss-amd-ance-arca-fadoi-gicr-iacpr-sici-gise-sibioc-sic-sicoa-sid-sif-simeu-simg-simi-sisa-joint-consensus-document-on-cholesterol-and-cardiovascular-risk-diagnostic-therapeutic-pathway-in-italy
#11
Michele Massimo Gulizia, Furio Colivicchi, Gualtiero Ricciardi, Simona Giampaoli, Aldo Pietro Maggioni, Maurizio Averna, Maria Stella Graziani, Ferruccio Ceriotti, Alessandro Mugelli, Francesco Rossi, Gerardo Medea, Damiano Parretti, Maurizio Giuseppe Abrignani, Marcello Arca, Pasquale Perrone Filardi, Francesco Perticone, Alberico Catapano, Raffaele Griffo, Federico Nardi, Carmine Riccio, Andrea Di Lenarda, Marino Scherillo, Nicoletta Musacchio, Antonio Vittorio Panno, Giovanni Battista Zito, Mauro Campanini, Leonardo Bolognese, Pompilio Massimo Faggiano, Giuseppe Musumeci, Enrico Pusineri, Marcello Ciaccio, Enzo Bonora, Giorgio Cantelli Forti, Maria Pia Ruggieri, Claudio Cricelli, Francesco Romeo, Roberto Ferrari, Attilio Maseri
Atherosclerotic cardiovascular disease still represents the leading cause of death in Western countries. A wealth of scientific evidence demonstrates that increased blood cholesterol levels have a major impact on the outbreak and progression of atherosclerotic plaques. Moreover, several cholesterol-lowering pharmacological agents, including statins and ezetimibe, have proved effective in improving clinical outcomes. This document focuses on the clinical management of hypercholesterolaemia and has been conceived by 16 Italian medical associations with the support of the Italian National Institute of Health...
May 2017: European Heart Journal Supplements: Journal of the European Society of Cardiology
https://www.readbyqxmd.com/read/28750477/anti-pcsk9-antibodies-for-hypercholesterolaemia-overview-of-clinical-data-and-implications-for-primary-care
#12
REVIEW
Olivier S Descamps, Uwe Fraass, Ricardo Dent, Winfried März, Ioanna Gouni-Berthold
OBJECTIVES: To put data from our recent systematic review of phase 3 studies of anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) antibodies into the context of clinical practice. METHODS: Data from studies previously identified by a systematic review of phase 3 studies of alirocumab and evolocumab and additional references from non-systematic literature searches were used. We evaluated the hypothetical cardiovascular (CV) benefit in cases of typical patients in whom anti-PCSK9 antibodies may be recommended, using preliminary major CV event (CVE) rates from long-term clinical trials of anti-PCSK9 antibodies and from extrapolations derived from correlation between low-density lipoprotein cholesterol (LDL-C) reduction and CV benefit with other lipid-lowering therapies (LLTs)...
July 27, 2017: International Journal of Clinical Practice
https://www.readbyqxmd.com/read/28736830/pcsk9-in-context-a-contemporary-review-of-an-important-biological-target-for-the-prevention-and-treatment-of-atherosclerotic-cardiovascular-disease
#13
REVIEW
Michael M Page, Gerald F Watts
Proprotein convertase subtilisin/kexin type 9 (PCSK9) and the identification of its critical role in lipoprotein metabolism has rapidly led to the development of PCSK9 inhibition with monoclonal antibodies (mAbs). PCSK9 mAbs are already in limited clinical use and are the subject of major cardiovascular outcomes trials, which if universally positive could see much wider clinical application of these agents. Patients with familial hypercholesterolaemia are the most obvious candidates for these drugs, but other patients with elevated cardiovascular risk, statin intolerance or hyperlipoproteinaemia(a) may also benefit...
July 24, 2017: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/28734741/beneficial-effects-of-tqrf-and-tq-nano-and-conventional-emulsions-on-memory-deficit-lipid-peroxidation-total-antioxidant-status-antioxidants-genes-expression-and-soluble-a%C3%AE-levels-in-high-fat-cholesterol-diet-induced-rats
#14
Norsharina Ismail, Maznah Ismail, Nur Hanisah Azmi, Muhammad Firdaus Abu Bakar, Zhang Yida, Johnson Stanslas, Dahiru Sani, Hamidon Basri, Maizaton Atmadini Abdullah
The study determined the effect of thymoquinone rich fraction (TQRF) and thymoquinone (TQ) in the forms of nano- and conventional emulsions on learning and memory, lipid peroxidation, total antioxidant status, antioxidants genes expression and soluble β-amyloid (Aβ) levels in rats fed with a high fat-cholesterol diet (HFCD). The TQRF was extracted from Nigella sativa seeds using a supercritical fluid extraction system and prepared into nanoemulsion, which later named as TQRF nanoemulsion (TQRFNE). Meanwhile, TQ was acquired commercially and prepared into thymoquinone nanoemulsion (TQNE)...
July 20, 2017: Chemico-biological Interactions
https://www.readbyqxmd.com/read/28726853/dyslipidaemia-effect-of-hypercholesterolaemia-on-hdl-particle-remodelling
#15
Gregory B Lim
No abstract text is available yet for this article.
September 2017: Nature Reviews. Cardiology
https://www.readbyqxmd.com/read/28725889/cholesterol-lowering-by-pediococcus-acidilactici-lab4-and-lactobacillus-plantarum-lab12-in-adult-zebrafish-is-associated-with-improved-memory-and-involves-an-interplay-between-npc1l1-and-abca1
#16
Fei Tieng Lim, Siong Meng Lim, Kalavathy Ramasamy
This study assessed the cholesterol lowering effect of Pediococcus acidilactici LAB4 and Lactobacillus plantarum LAB12 using adult zebrafish. Animals were fed with a high cholesterol diet (HCD) with/without LAB for seven weeks. Serum and liver cholesterol was quantified using colorimetric and dye staining methods. Expressions of npc1l1 and abca1 in the liver and intestine and appa in the brain were quantified using RT-PCR. Serum and liver cholesterol was significantly lowered in LAB4- and LAB12-fed zebrafish (≤64% and ≤71%, respectively), with reduced liver cholesterol deposition...
August 1, 2017: Food & Function
https://www.readbyqxmd.com/read/28718675/the-evolving-model-of-care-for-familial-hypercholesterolaemia
#17
Gerald F Watts, Jing Pang
No abstract text is available yet for this article.
January 1, 2017: European Journal of Preventive Cardiology
https://www.readbyqxmd.com/read/28701353/known-and-unknowns-in-the-care-of-paediatric-familial-hypercholesterolaemia
#18
Andrew C Martin, Samuel S Gidding, Albert Wiegman, Gerald F Watts
Familial hypercholesterolaemia (FH) is a common genetic disorder that causes elevated low-density lipoprotein (LDL)-cholesterol levels from birth. Untreated FH accelerates atherosclerosis and predisposes individuals to premature coronary artery disease (CAD) in adulthood. Mendelian randomization studies have demonstrated that LDL-cholesterol has both a causal and cumulative effect on the risk of CAD. This supports clinical recommendations that children with FH commence pharmacological treatment from age 8-10 years, to reduce the burden of hypercholesterolaemia...
July 12, 2017: Journal of Lipid Research
https://www.readbyqxmd.com/read/28684113/sericin-improves-heart-and-liver-mitochondrial-architecture-in-hypercholesterolaemic-rats-and-maintains-pancreatic-and-adrenal-cell-biosynthesis
#19
Sumate Ampawong, Duangnate Isarangkul, Pornanong Aramwit
Hypercholesterolaemia is well known to be associated with mitochondrial dysfunction, subsequently leading to multiple organ failure. Similar to other natural products, sericin is a candidate for adjunctive therapy in hyperlipidaemic conditions. However, the cholesterol-lowering mechanisms of sericin are multifactorial and controversial. Here, a high-cholesterol-fed rat model with or without sericin treatment was established using a dosage of 1,000mg/kg/day for 30 days. Blood lipid profiles, oxidative stress markers (superoxide dismutase, SOD; malondialdehyde, MDA; nuclear factor erythroid 2-related factor, Nrf-2), dysmorphic mitochondria in relation to fission (dynamin-related protein-1; Drp-1) and fusion (guanosine triphosphatase mutated in dominant optic atrophy; OPA-1) markers and biosynthetic markers (aquaporin, AQP-1; tubulin-4β, Tb4B) in the pancreas and adrenal gland were evaluated...
July 3, 2017: Experimental Cell Research
https://www.readbyqxmd.com/read/28674132/exploration-into-lipid-management-and-persistent-risk-in-patients-hospitalised-for-acute-coronary-syndrome-in-japan-explore-j-protocol-for-a-prospective-observational-study
#20
Masato Nakamura, Kiyoko Uno, Atsushi Hirayama, Junya Ako, Atsushi Nohara, Hidenori Arai, Mariko Harada-Shiba
INTRODUCTION: The present study is the largest registry study ever conducted in Japan exploring the prevalence of familial hypercholesterolaemia (FH) among patients with acute coronary syndrome (ACS). Our study aims to (1) evaluate the status of lipid management and the subsequent risk of major cardiovascular events following hospitalisation of Japanese patients with ACS in real-world clinical practice; (2) determine the proportion of Japanese patients with ACS who achieve the lipid management goal and have a reduction of event risks with strict lipid management (low-density lipoprotein-cholesterol <1...
July 2, 2017: BMJ Open
keyword
keyword
73339
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"